Skip to main content

PPIs Protective for Esophageal Cancer

Patients with Barrett’s esophagus (BE) who are treated with proton pump inhibitors (PPIs) have a significantly decreased risk for progression to high-grade dysplasia or esophageal adenocarcinoma (EAC), a recent systematic analysis presented at the 2014 American Society for Clinical Oncology Gastrointestinal Cancers Symposium showed.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino